Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The thalidomide saga.

Magda Melchert1, Alan List

  • 1Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. Melcheme@moffitt.usf.edu

The International Journal of Biochemistry & Cell Biology
|March 21, 2007
PubMed
Summary

Thalidomide and its analogs are immunomodulatory drugs (IMiDs) that treat cancer and inflammatory diseases by suppressing cytokines and angiogenesis. These drugs, including lenalidomide, show promise in various conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell cycle arrest: A breakthrough in the supportive care of older cancer patients.

Journal of the American Geriatrics Society·2023
Same author

A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest.

Drugs & aging·2023
Same author

Correction to: New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.

Current oncology reports·2022
Same author

New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.

Current oncology reports·2022
Same author

The role of innate immunity in MDS pathogenesis.

HemaSphere·2022
Same author

Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.

Cancer medicine·2020

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Thalidomide, initially a sedative, is now recognized as an immunomodulatory drug (IMiD).
  • It exhibits anti-inflammatory and anti-angiogenic properties by modulating cytokine production and signaling pathways.
  • Its analogs, lenalidomide and CC-4047, offer enhanced potency and therapeutic potential.

Purpose of the Study:

  • To review the pharmacokinetic and biologic effects of thalidomide and its analogs.
  • To explore their mechanisms of action in malignant and inflammatory conditions.
  • To discuss their therapeutic applications and ongoing investigations.

Main Methods:

  • Literature review of studies on thalidomide and its analogs.
  • Analysis of biological effects, including cytokine modulation, T-cell activation, and angiogenesis inhibition.
  • Examination of pharmacokinetic profiles and clinical applications.

Main Results:

  • Thalidomide suppresses tumor necrosis factor-alpha (TNF-alpha) and pro-inflammatory cytokines.
  • It inhibits vascular endothelial growth factor (VEGF) and beta fibroblast growth factor (bFGF), antagonizing neoangiogenesis.
  • Lenalidomide and CC-4047 demonstrate enhanced potency in these effects and are approved for multiple myeloma and myelodysplastic syndromes.

Conclusions:

  • Thalidomide and its analogs are effective immunomodulatory drugs with broad therapeutic applications.
  • Their mechanisms involve cytokine suppression, T-cell activation, and anti-angiogenesis.
  • Ongoing research continues to explore their potential in various cancers and inflammatory diseases.

Related Experiment Videos